Exscientia PLC
NASDAQ:EXAI
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.99
7.51
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one EXAI stock under the Base Case scenario is 5.2 USD. Compared to the current market price of 5.58 USD, Exscientia PLC is Overvalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Exscientia PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for EXAI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Exscientia PLC
Balance Sheet Decomposition
Exscientia PLC
Current Assets | 404.9m |
Cash & Short-Term Investments | 361.2m |
Receivables | 35.9m |
Other Current Assets | 7.9m |
Non-Current Assets | 105.8m |
Long-Term Investments | 3m |
PP&E | 67.5m |
Intangibles | 34.6m |
Other Non-Current Assets | 663k |
Current Liabilities | 65.1m |
Accounts Payable | 11.3m |
Accrued Liabilities | 22.2m |
Other Current Liabilities | 31.5m |
Non-Current Liabilities | 89.9m |
Long-Term Debt | 16.5m |
Other Non-Current Liabilities | 73.4m |
Earnings Waterfall
Exscientia PLC
Revenue
|
21m
GBP
|
Cost of Revenue
|
-27.8m
GBP
|
Gross Profit
|
-6.8m
GBP
|
Operating Expenses
|
-142.4m
GBP
|
Operating Income
|
-149.2m
GBP
|
Other Expenses
|
19.6m
GBP
|
Net Income
|
-129.6m
GBP
|
Free Cash Flow Analysis
Exscientia PLC
GBP | |
Free Cash Flow | GBP |
In Q1 2024, Exscientia achieved a 29% reduction in cash burn, extending its cash runway into 2027. The company anticipates significant milestones with its clinical pipeline, particularly with CDK7 and LSD1 inhibitors, which are expected to deliver data later this year. The automation lab, now fully operational, significantly reduces costs and accelerates discovery processes. Strategic partnerships with firms like Sanofi and Merck are anticipated to generate hundreds of millions in milestones. By cutting 20-25% of global staff, the company will realize $40 million in annualized savings starting in 2025 .
What is Earnings Call?
EXAI Profitability Score
Profitability Due Diligence
Exscientia PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Exscientia PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
EXAI Solvency Score
Solvency Due Diligence
Exscientia PLC's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Exscientia PLC's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EXAI Price Targets Summary
Exscientia PLC
According to Wall Street analysts, the average 1-year price target for EXAI is 5.46 USD with a low forecast of 5.05 USD and a high forecast of 5.99 USD.
Dividends
Current shareholder yield for EXAI is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.
Contact
IPO
Employees
Officers
The intrinsic value of one EXAI stock under the Base Case scenario is 5.2 USD.
Compared to the current market price of 5.58 USD, Exscientia PLC is Overvalued by 7%.